Leukemia, Myeloid, Chronic-Phase
Conditions
Brief summary
Patients will be randomized in phase II trials to continue on the same TKI versus one of the alternative treatment approaches. If a patient is not eligible for one of the treatments, he (she) will be randomized between the options for which he (she) is eligible. The trial will start with current available treatment options (experimental arms). New available treatment options may be open at any times later on. Authorized TKIs are imatinib, nilotinib, dasatinib, bosutinib and ponatinib. For all options the treatment duration is for a minimum of 12 months and will be continued in the absence of adverse events following investigator decision. Each therapeutic option will be detailed in term of combination modalities, dose, dose adaptation, specific warnings, specific exclusion and inclusion criteria. The decision to introduce a new option will depend on the general pace of recruitment and on the assessment of the potential efficacy and safety of the new treatment, and will be implemented after scientific review by a protocol amendment. Primary objective: A. To select molecules in combination or sequentially with imatinib, nilotinib, dasatinib, bosutinib or ponatinib potentially able to produce a 25% increase in the Cumulative Incidence of MR4.5 as compare to control. Secondary objectives: A. To determine the safety of selected therapies B. To determine the rate of MR4 by 12, 24, 36, 48 months in experimental and control arms C. To determine the rates of MR4.5 by 24, 36, 48 months in experimental and control arms D. To determine the rate of undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 12, 24, 36, 48 months in experimental and control arms E. To estimate treatment free remission (TFR) in patients eligible for discontinuation studies F. To investigate the relationship between biological activity and the clinical efficacy of the selected therapies G. To assess the effects of the treatments on the number and clonogenicity of CML stem cells and other biological markers of interest H. To estimate duration of response, progression-free survival, event free survival and overall survival.
Detailed description
Patients will be randomised to continue on TKI (same daily dose) versus one of the alternative novel treatment approaches. If a patient is not eligible for one of the treatments, he can be randomised for the options for which he is eligible. All treatment options may be open at all times. Investigators must specify before randomization for which treatment option they want their patient be included and randomized. Perspectives New treatment options will be introduced over time. The decision to introduce a new option will depend on the general pace of recruitment and the assessment of the potential efficacy and safety of the new treatment in this patient population, and will be implemented after scientific review by a protocol amendment. The available treatment arms are: 1. TKI alone same daily dose (control arm) 2. TKI in combination with pioglitazone 3. TKI in combination with Avelumab (anti-PD-L1 antibody) Planned treatment arms for the future may be : 1. TKI in combination with pegylated interferon 2. TKI in combination with arsenic trioxide 3. TKI in combination with Homoharringtonine Protocol plan: 1. Control arm (Imatinib, nilotinib, dasatinib, bosutinib or ponatinib): Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months 2. Pioglitazone arm * TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months * PIOGLITAZONE (Actos®): 30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in the absence of grade \>1 related AE. * After 12 Months : Continue TKI at the same daily dose and STOP pioglitazone. 3. AVELUMAB arm * TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months * AVELUMAB: 10mg/kg every 2 weeks, for a maximum of 8 IV infusions over a 4 months' period. (If MR4.5 is acheived by the first 3 months the 7th and 8th infusions will be omitted) * After 12 Months :Continue TKI at the same daily dose. 4. Other experimental arm TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months * Arsenic trioxide : to be determined after amendment * Pegylated Interferon : to be determined after amendment * Homoharringtonine : to be determined after amendment * Drug X * Drug Y
Interventions
DRUGPioglitazone
PIOGLITAZONE (Actos®): 30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in the absence of grade \>1 related AE.
DRUGAvelumab
10mg/kg every 2 weeks, for a maximum of 8 IV infusions over a 4 months' period. (If MR4.5 is acheived by the first 3 months the 7th and 8th infusions will be omitted)
Sponsors
Versailles Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Common Inclusion Criteria: 1. Patient aged 18y or more 2. Signed informed consent 3. Patient with Philadelphia chromosome positive chronic phase CML and M BCR-ABL1 transcript positivity at diagnosis 4. Treatment with imatinib, nilotinib, dasatinib or bosutinib for more than 2 years overall 5. No switch between tyrosine kinase inhibitors within the last 3 months 6. No dose modification within the last 3 months 7. Complete cytogenetic response or BCR-ABL1IS ≤ 1% 8. Detectable BCR-ABL1 with BCR-ABL1IS \> 0.0032% (less than MR4.5) 9. ECOG grade 0 to 2 10. ASAT and ALAT ≤ 2.5 N 11. Bilirubin in serum ≤ 2.5 N 12. Men and Women of childbearing potential must be using an adequate method of contraception These specific inclusion criteria will apply for the Avelumab arm in addition to the common criteria. 1. Hematologic: 1. Absolute neutrophil count (ANC) ≥ 1.5 × 109/L, 2. Platelet count ≥ 100 × 109/L, 3. Hemoglobin ≥ 9 g/dL. (may have been transfused). 2. Hepatic: a. Total bilirubin level ≤ 1.5 × the upper limit of normal (ULN) range. 3. Renal: Estimated creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault formula (or local institutional standard method) 4. Pregnancy test: Negative serum or urine pregnancy test at screening for women of childbearing potential. 5. Contraception: Highly effective contraception for both male and female subjects throughout the study and for at least 30 days after last Avelumab treatment administration if the risk of conception exists. Common
Exclusion criteria
1. Pregnant or lactating women, 2. Participation in another clinical trial with any investigative drug within 30 days prior to study enrolment, 3. Prior history of hematopoietic stem cell transplantation (autologous or allogenic) 4. Cardiovascular disease: * Stage II to IV congestive heart failure (CHF) as determined by the New York Heart Association (NYHA) classification system for heart failure. * Myocardial infarction within the previous 6 months * Symptomatic cardiac arrhythmia requiring treatment 5. Grade III or IV fluid retention 6. Known BCR-ABL kinase domain mutation 7. CML patient not in chronic phase at diagnosis 8. Individuals with an active malignancy 9. Known HIV-positivity These specific
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cumulative incidence of patients achieving a deep molecular response | 12 months | The cumulative incidence of patients achieving a deep molecular response defined by MR4.5 or deeper (BCR-ABLIS ≤ 0.0032 %) by 12 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events | 12 Months | Adverse events |
| The cumulative rate of patients achieving MR4.5 by 24months in experimental and control arms | 24 months | The cumulative rate of patients achieving MR4.5 by 24months in experimental and control arms |
| The cumulative rate of patients achieving MR4.5 by 36 months in experimental and control arms | 36 months | The cumulative rate of patients achieving MR4.5 by 36 months in experimental and control arms |
| The cumulative rate of patients achieving MR4.5 by 48 months in experimental and control arms | 48 months | The cumulative rate of patients achieving MR4.5 by 48months in experimental and control arms |
| The cumulative rate of patients achieving MR4 by 12months in experimental and control arms | 12 months | The cumulative rate of patients achieving MR4 by 12,months in experimental and control arms |
| The cumulative rate of patients achieving MR4 by 24 months in experimental and control arms | 24 months | The cumulative rate of patients achieving MR4 by 24 months in experimental and control arms |
| The cumulative rate of patients achieving MR4 by 36 months in experimental and control arms | 36 months | The cumulative rate of patients achieving MR4 by 36 months in experimental and control arms |
| The cumulative rate of patients achieving MR4 by 48 months in experimental and control arms | 48 months | The cumulative rate of patients achieving MR4 by 48 months in experimental and control arms |
| The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 12months in experimental and control arms | 12 months | The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 12months in experimental and control arms |
| The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 36 months in experimental and control arms | 36 months | The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 36 months in experimental and control arms |
| The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 48 months in experimental and control arms | 48 months | The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 48 months in experimental and control arms |
| The rate of patients in treatment free remission during follow-up | 48 months | The rate of patients in treatment free remission during follow-up |
| Quantification of CML- and normal-CFU in bone marrow by clonogenic assays and RTQ- PCR | 12 months | — |
| Survival | 48 months | Survival |
| duration of response | 48 months | duration of response |
| event free survival | 48 months | event free survival |
| progression free survival | 48 months | progression free survival |
| The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 24months in experimental and control arms | 24 months | The cumulative rate of patients with undetectable BCR-ABL1 transcript (sensitivity 40000 ABL copies) by 24, months in experimental and control arms |
Countries
France
Contacts
Primary ContactLaure MORISSET
Outcome results
None listed